0
0

Medical Innovation Acceleration Act of 2023

1/19/2024, 4:38 AM

Congressional Summary of HR 71

Medical Innovation Acceleration Act of 2023

This bill exempts noninvasive diagnostic devices from the regulatory authority of the Food and Drug Administration.

The bill defines noninvasive diagnostic device as one that does not penetrate the skin or any other membrane of the body, is not inserted or implanted into the body, causes no more than ephemeral compression or temperature changes to in situ bodily tissues, and does not subject bodily tissues to ionizing radiation.

Current Status of Bill HR 71

Bill HR 71 is currently in the status of Bill Introduced since January 9, 2023. Bill HR 71 was introduced during Congress 118 and was introduced to the House on January 9, 2023.  Bill HR 71's most recent activity was Referred to the House Committee on Energy and Commerce. as of January 9, 2023

Bipartisan Support of Bill HR 71

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 71

Primary Policy Focus

Health

Potential Impact Areas

- Administrative remedies
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)

Alternate Title(s) of Bill HR 71

Medical Innovation Acceleration Act of 2023
Medical Innovation Acceleration Act of 2023
To amend the Federal Food, Drug, and Cosmetic Act to exempt from regulation as devices non-invasive diagnostic devices, and for other purposes.

Comments